Effect of L-Carnitine Supplementation on Circulating C-Reactive Protein Levels: A Systematic Review and Meta-Analysis / Uticaj Suplementacije L-Karnitinom Na Nivoe C-Reaktivnog Proteina U Cirkulaciji: Sistematski Pregled I Metaanaliza

Abstract

SummaryBackgroundC-reactive protein (CRP) has been proposed as a risk marker and risk factor of cardiovascular disease. There have been a number of clinical reports suggesting that supplementation with L-carnitine can modulate systemic inflammation and lower circulating CRP concentrations, but the results have not been consistent.MethodsA comprehensive literature search in Medline, Scopus and Cochrane Central Register of Controlled Trials was performed in December 2012 to identify clinical trials investigating the impact of oral L-carnitine supplementation on serum/plasma CRP concentration. A random effect method was used to calculate the combined effect size.ResultsSix studies comprising 541 cases and 546 controls met the inclusion criteria. Meta-analysis of included trials revealed a significant reduction of circulating CRP concentrations in subjects under L-carnitine intervention compared to the control treatment. The calculated combined weighted mean reduction in CRP concentrations was −0.39 mg/L [95% CI (−0.62 – −0.16)]. This effect size estimate was found to be robust and remained unaffected by the removal of each single study.ConclusionsThe overall findings of the present meta-analysis support the clinically relevant benefit of L-carnitine supplementation in lowering the circulating levels of CRP.

L-Carnitine Supplementation could improve Clinical Symptom but not effect on C- reactive Protein and Malondialdehyde in Obese Women with Knee Osteoarthritis: A Double Blind Randomized Controlled Trial

“…Furthermore, a study on hemodialysis patients with hyper lipo-proteinemia reported that 1000 mg/d of oral L-carnitine could reduce in ammation but didn't affect oxidative stress [33]. Moreover, a meta-analysis con rmed that L-carnitine can reduce CRP [13]. In comparison with the current research, CRP reduction in this study may be due to injection of L-carnitine and longer duration of the study.…”

“…Earlier studies showed that L-carnitine can signi cantly reduce CRP and MDA in coronary [29,30] and hemodialysis patients [31]. Meta-analysis also showed that L-carnitine supplementation signi cantly reduced the levels of CRP [13], cholesterol and lowdensity lipoprotein cholesterol (LDL-C) in diabetic patients [14]. Recent study also reported that 750 mg of Lcarnitine supplementation had no effect on serum lipid pro le and hs-CRP in women with KOA [15,16].…”

The Influence of L-Carnitine in the Complex Treatment of Patients with Renal Dysfunction Who Have Synchronous Chronic Coronary Artery Disease and Prostate Adenocarcinoma

“…Particularly, the deficiency in L-Carnitine may be associated with a syndrome of progressive skeletal myopathy and cardiomyopathy. 17,18 Thus, L-Carnitine may be useful in patients with toxic injuries, particularly in oncology profile patients.…”

The effect of l‐carnitine supplementation on serum levels of omentin‐1, visfatin and SFRP5 and glycemic indices in patients with pemphigus vulgaris: A randomized, double‐blind, placebo‐controlled clinical trial

“…LC has been reported to increase antioxidant enzyme activity and to regulate fatty acid and glucose metabolism for energy balance (Calvani, Reda, & Arrigoni‐Martelli, ). Prior studies have suggested that LC supplementation has beneficial effects on metabolic syndrome components such as hyperlipidemia (Askarpour et al, ), hypertension (Askarpour et al, ), insulin resistance (Xu et al, ), and oxidative stress and inflammation (Mohammadi et al, ; Nazary‐vannani et al, ; Sahebkar, ).…”